EICHORCondition: Recurrent Basal Cell Carcinoma · Sponsor: Sol-Gel Technologies, Ltd.
This is a multicenter, randomized, double-blind, stratified, vehicle-controlled study of the efficacy and safety of Patidegib Topical Gel, 2%, applied topically twice daily to the face of adult participants with non-Gorlin HF-BCC (high-frequency basal cell carcinoma). Participants will be randomized (1:1) to receive either Patidegib Topical Gel, 2%, or Vehicle for 9 months. Randomization will be stratified by gender. The primary endpoint is the number of nSEB (surgically eligible basal cell carcinoma) that develop on the face over the 9 month period. The primary end point will be assessed by imaging and tracking of BCCs consistently throughout the study in order to identify nSEBs.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Axiom Research, LLC | Apple Valley, California, United States | — |
| Axiom Research, LLC | Colton, California, United States | — |
| Center for Dermatology Clinical Research, Inc. | Fremont, California, United States | — |
| Dermatology Research Associates | Los Angeles, California, United States | — |
| The Dermatology Center of Newport | Newport Beach, California, United States | — |
| Palm Beach Dermatology Research | Delray Beach, Florida, United States | — |
| Leavitt Medical Associates of Florida | Ormond Beach, Florida, United States | — |
| PellePharm Investigative Site | Saint Augustine, Florida, United States | — |
| The Indiana Clinical Trials Center | Plainfield, Indiana, United States | — |
| Grekin Skin Institute | Warren, Michigan, United States | — |
| PellePharm Investigative Site | Henderson, Nevada, United States | — |
| Skin Laser and Surgery Specialists of NY&NJ | Hackensack, New Jersey, United States | — |
+ 2 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04155190